Molecular Stability as a Translational Gate: A Structured Framework for Target Validation in Genetic Cardiomyopathy.

The dominant translational error in genetic cardiomyopathy is the treatment of pathogenicity annotation and mechanistic plausibility as jointly sufficient for clinical advancement, absent evidence that a target's molecular consequences are both stable and reproducible across independent patient cohorts. This perspective argues that molecular stability is a function of mechanism and not of genetic evidence and that cross-cohort concordance must serve as an explicit development gate alongside mechanistic plausibility. We synthesize published evidence across sarcomeric biology, calcium signaling, fibrosis, metabolic remodeling, and immune crosstalk in hypertrophic cardiomyopathy and dilated cardiomyopathy and critically evaluate how biological heterogeneity, incomplete penetrance, and model limitations introduce translational risk that currently goes unquantified. Evidence is organized by mechanistic domain and evaluated for reproducibility strength using a structured synthesis approach. A seven-step translational framework is proposed, operationalized through a five-domain Molecular Concordance Scoring Matrix. The matrix is presented as one implementation of the broader principle that stability must be demonstrated, not assumed, and is the binding contribution. An illustrative evidence map for representative cardiomyopathy targets is provided, with expected concordance tiers grounded in published mechanistic evidence. This framework identifies cardiomyopathy as an exemplar of a broader problem in genetically anchored but molecularly heterogeneous disease and specifies the empirical agenda required to validate and generalize it.